NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.55 million. Kindred Biosciences had a negative net margin of 1,461.28% and a negative return on equity of 58.86%. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

8 analysts have issued 12 month target prices for Kindred Biosciences' stock. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' stock price to reach $14.44 in the next year. This suggests a possible upside of 52.0% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Media stories about KIN stock have trended extremely negative recently, according to InfoTrie. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kindred Biosciences earned a news impact score of -4.5 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 671,100 shares, a decline of 5.5% from the November 28th total of 709,900 shares. Based on an average trading volume of 98,200 shares, the short-interest ratio is presently 6.8 days. Approximately 1.8% of the shares of the company are short sold. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Theravance Biopharma (TBPH), Innoviva (INVA), Esperion Therapeutics (ESPR), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL) and IGM Biosciences (IGMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $9.50.

Kindred Biosciences has a market capitalization of $371.36 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

The official website for Kindred Biosciences is http://kindredbio.com/.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]